A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

October 30, 2028

Study Completion Date

October 30, 2028

Conditions

Locally Advanced Solid TumorMetastatic Solid Tumor

Interventions

BIOLOGICAL

IPN60300

IPN60300 will be administered at assigned dose level.